Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Keros Therapeutics Inc is a biotechnology business based in the US. Keros Therapeutics Inc shares (KROS) are listed on the NASDAQ and all prices are listed in US Dollars. Keros Therapeutics Inc employs 75 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $26.03 |
|---|---|
| 52-week range | $24.38 - $68.29 |
| 50-day moving average | $42.06 |
| 200-day moving average | $47.63 |
| Wall St. target price | $93.75 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.85 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $26.03 from 2022-06-28
| 1 week (2022-06-22) | -1.55% |
|---|---|
| 1 month (2022-05-27) | -25.95% |
| 3 months (2022-03-30) | -51.49% |
| 6 months (2021-12-30) | -53.77% |
| 1 year (2021-06-30) | -38.71% |
|---|---|
| 2 years (2020-06-30) | -30.61% |
| 3 years (2019-06-26) | N/A |
| 5 years (2017-06-26) | N/A |
| Revenue TTM | $20.1 million |
|---|---|
| Gross profit TTM | $-35,043,000 |
| Return on assets TTM | -16.42% |
| Return on equity TTM | -28.42% |
| Profit margin | 0% |
| Book value | $9.31 |
| Market capitalisation | $686.4 million |
TTM: trailing 12 months
We're not expecting Keros Therapeutics Inc to pay a dividend over the next 12 months.
Over the last 12 months, Keros Therapeutics Inc's shares have ranged in value from as little as $24.38 up to $68.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Keros Therapeutics Inc's is 1.2249. This would suggest that Keros Therapeutics Inc's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. .
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Everything we know about the NYIAX IPO, plus information on how to buy in.
Everything we know about the Adamas One Corp IPO, plus information on how to buy in.
Everything we know about the Glucose Health IPO, plus information on how to buy in.
Everything we know about the Boustead Wavefront IPO, plus information on how to buy in.
Everything we know about the ParaZero Technologies IPO, plus information on how to buy in.